About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Genome Editing Market Size, Share, CAGR of 16.9%, Forecast to 2031
Genome Editing Market

Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, TALEN, ZFN), By Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Other Applications), By End-User (Pharmaceutical and Biotechnology Companies, Academics and Government Research Institutes, Contract Research Organizations, Other End Users) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI884DR
Last Updated : August 12, 2024
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Genome Editing Market Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. CRISPR
        1. By Value
      3. TALEN
        1. By Value
      4. ZFN
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Cell Line Engineering
        1. By Value
      3. Animal Genetic Engineering
        1. By Value
      4. Plant Genetic Engineering
        1. By Value
      5. Other Applications
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnology Companies
        1. By Value
      3. Academics and Government Research Institutes
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Other End Users
        1. By Value
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. CRISPR
        1. By Value
      3. TALEN
        1. By Value
      4. ZFN
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Cell Line Engineering
        1. By Value
      3. Animal Genetic Engineering
        1. By Value
      4. Plant Genetic Engineering
        1. By Value
      5. Other Applications
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnology Companies
        1. By Value
      3. Academics and Government Research Institutes
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Other End Users
        1. By Value
    5. U.S.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. CRISPR
          1. By Value
        3. TALEN
          1. By Value
        4. ZFN
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Cell Line Engineering
          1. By Value
        3. Animal Genetic Engineering
          1. By Value
        4. Plant Genetic Engineering
          1. By Value
        5. Other Applications
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnology Companies
          1. By Value
        3. Academics and Government Research Institutes
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Other End Users
          1. By Value
    6. Canada
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. CRISPR
        1. By Value
      3. TALEN
        1. By Value
      4. ZFN
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Cell Line Engineering
        1. By Value
      3. Animal Genetic Engineering
        1. By Value
      4. Plant Genetic Engineering
        1. By Value
      5. Other Applications
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnology Companies
        1. By Value
      3. Academics and Government Research Institutes
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Other End Users
        1. By Value
    5. U.K.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. CRISPR
          1. By Value
        3. TALEN
          1. By Value
        4. ZFN
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Cell Line Engineering
          1. By Value
        3. Animal Genetic Engineering
          1. By Value
        4. Plant Genetic Engineering
          1. By Value
        5. Other Applications
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnology Companies
          1. By Value
        3. Academics and Government Research Institutes
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Other End Users
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. CRISPR
        1. By Value
      3. TALEN
        1. By Value
      4. ZFN
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Cell Line Engineering
        1. By Value
      3. Animal Genetic Engineering
        1. By Value
      4. Plant Genetic Engineering
        1. By Value
      5. Other Applications
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnology Companies
        1. By Value
      3. Academics and Government Research Institutes
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Other End Users
        1. By Value
    5. China
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. CRISPR
          1. By Value
        3. TALEN
          1. By Value
        4. ZFN
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Cell Line Engineering
          1. By Value
        3. Animal Genetic Engineering
          1. By Value
        4. Plant Genetic Engineering
          1. By Value
        5. Other Applications
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnology Companies
          1. By Value
        3. Academics and Government Research Institutes
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Other End Users
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. CRISPR
        1. By Value
      3. TALEN
        1. By Value
      4. ZFN
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Cell Line Engineering
        1. By Value
      3. Animal Genetic Engineering
        1. By Value
      4. Plant Genetic Engineering
        1. By Value
      5. Other Applications
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnology Companies
        1. By Value
      3. Academics and Government Research Institutes
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Other End Users
        1. By Value
    5. UAE
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. CRISPR
          1. By Value
        3. TALEN
          1. By Value
        4. ZFN
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Cell Line Engineering
          1. By Value
        3. Animal Genetic Engineering
          1. By Value
        4. Plant Genetic Engineering
          1. By Value
        5. Other Applications
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnology Companies
          1. By Value
        3. Academics and Government Research Institutes
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Other End Users
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. CRISPR
        1. By Value
      3. TALEN
        1. By Value
      4. ZFN
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Cell Line Engineering
        1. By Value
      3. Animal Genetic Engineering
        1. By Value
      4. Plant Genetic Engineering
        1. By Value
      5. Other Applications
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnology Companies
        1. By Value
      3. Academics and Government Research Institutes
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Other End Users
        1. By Value
    5. Brazil
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. CRISPR
          1. By Value
        3. TALEN
          1. By Value
        4. ZFN
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Cell Line Engineering
          1. By Value
        3. Animal Genetic Engineering
          1. By Value
        4. Plant Genetic Engineering
          1. By Value
        5. Other Applications
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnology Companies
          1. By Value
        3. Academics and Government Research Institutes
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Other End Users
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Genome Editing Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Merck KGaA (Germany)
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. GenScript (China)
    3. Sangamo Therapeutics (U.S.)
    4. Lonza (Switzerland)
    5. Editas Medicine (U.S.)
    6. CRISPR Therapeutics (Switzerland)
    7. Tecan Trading AG (Switzerland)
    8. Precision Biosciences (U.S.)
    9. Cellectis S.A (France)
    10. Genome Medical, Inc. (U.S.)
    11. BioMed Central Ltd (U.K.)
    12. Aevi Genomic Medicine, Inc. (Israel)
    13. Congenica Ltd. (U.K.)
    14. Deep Genomics (Canada)
    15. Illumina, Inc. (U.S.)
    16. Thermo Fisher Scientific Inc. (U.S.)
    17. QIAGEN N.V. (Netherlands)
    18. Agilent Technologies, Inc. (U.S.)
    19. Bio-Rad Laboratories, Inc. (U.S.)
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
CRISPR Gene Editing Market Size & Trends The global CRISPR gene editing market size was valued at USD 3.44 billion in 2023. It is expected to reach USD 25.28 billion in 2032, growing at a CAGR of 24.81% over the forecast period (2024-32). CRISPR
Buy Now
Global Report
Genetic Testing Market Size The global genetic testing market size was worth USD 14.82 billion in 2021 and is projected to reach USD 36.11 billion by 2030, growing at a CAGR of 10% during the forecast period (2022-2030).  Genetic testing
Buy Now
Global Report
Genome Sequencing Market Size The global genome sequencing market size was valued at USD 41.92 billion in 2023 and is projected to reach USD 101.23 billion by 2032, growing at a CAGR of 11.7% during the forecast period (2024–2032). Genome sequencin
Buy Now
Global Report
Home Bedding Market Size The global home bedding market was valued at USD 109.75 billion in 2024 and is estimated to reach from USD 119.08 billion in 2025 to USD 228.70 billion by 2033, growing at a CAGR of 8.5% during the forecast period (2025
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.